Navigation Links
Scientists can now differentiate between healthy cells and cancer cells
Date:1/5/2009

One of the current handicaps of cancer treatments is the difficulty of aiming these treatments at destroying malignant cells without killing healthy cells in the process. But a new study by McMaster University researchers has provided insight into how scientists might develop therapies and drugs that more carefully target cancer, while sparing normal healthy cells

Mick Bhatia, scientific director of the McMaster Stem Cell and Cancer Research Institute in the Michael G. DeGroote School of Medicine, and his team of investigators have demonstrated for the first time the difference between normal stem cells and cancer stem cells in humans.

The discovery, published in the prestigious journal Nature Biotechnology today, could eventually help with the further customization and targeting of cancer treatments for the individual patient. It will immediately provide a model to discover drugs using robotic screening for available molecules that may have untapped potential to eradicate cancer.

"Normal stem cells and cancer stem cells are hard to tell apart, and many have misconstrued really good stem cells for cancer stem cells that have gone bad - we now can tell the ones masquerading as normal stem cells from the bad, cancerous ones," said Bhatia.

"This also allows us to compare normal versus cancer stem cells from humans in the laboratory - define the differences in terms of genes they express and drugs they respond to. Essentially, we can now use this to find the "magic bullet", a drug or set of drugs that kill cancer stem cells first, and spare the normal healthy ones," he said.

"McMaster is uniquely positioned for this discovery platform, and this was the missing ingredient - we have one of the best screening/robotic platforms, chemical libraries and expertise in professors Eric Brown and Gerry Wright, who have discovered molecules to combat infectious disease. Now we can combine it all. This team now aims to k
'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Page: 1 2

Related biology news :

1. UK scientists working to help cut ID theft
2. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
3. Comet probes reveal evidence of origin of life, scientists claim
4. Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA
5. Male elephants get photo IDs from scientists
6. Scientists retrace evolution with first atomic structure of an ancient protein
7. Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
8. Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs
9. Clemson scientists shed light on molecules in living cells
10. Scientists tackle mystery mountain illness
11. T. rex quicker than Becks, say scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... be cultivated efficiently, they are anything but sustainable: ... monoculture cultivation is becoming increasingly evident. Despite their ... and are regarded as the sole possibility of ... wrongfully, finds Bernhard Schmid, an ecology professor at ... form of agriculture and forestry. After all, a ...
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
Breaking Biology News(10 mins):Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
... E or a combination of the supplements had a similar ... supplements, according to data from a randomized controlled trial in ... the National Cancer Institute. Epidemiological studies have suggested ... and thus antioxidants, may have a lower risk of cancer. ...
... has the honour of becoming the first student from ... competition that pitted engineering students and young professionals from ... the Institution of Engineering and Technology (IET), UK, the ... Mechanical & Aerospace Engineering beat three other contestants in ...
... Is Sensitive to Irradiation Researchers led by ... irradiation damages fat tissue. They report their findings in ... of Pathology . Radiation therapy directed ... of tissues such as fat tissue has often been ...
Cached Biology News:Vitamins C and E and beta carotene again fail to reduce cancer risk in randomized controlled trial 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 2NTU undergrad is first Singapore champion of an internationally acclaimed engineering competition 3Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5
(Date:10/18/2014)... The Asian arthroscopic devices report defines and ... forecast of revenue. The arthroscopic devices market in Asia ... at a CAGR of 6.5% from 2013 to 2018. ... devices market, to get an idea of the in-depth ... segmentation of arthroscopic devices market in the same region, ...
(Date:10/18/2014)... October 18, 2014 The Asian Electronic Medical ... in Asian with analysis and forecast of revenue. The electronic ... grow to $2,328.0 million by 2018, at a CAGR of ... of the Asian Electronic Medical Record (EMR) market, to get ... a glimpse of the segmentation of the market in the ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
(Date:10/17/2014)... Alice,s journey through the looking-glass to Wonderland, mirrors in ... unexpected ways, including a new class of mirror that ... in The Optical Society,s (OSA) new high-impact journal ... first time, a new type of mirror that forgoes ... light by using an unusual magnetic property of a ...
Breaking Biology Technology:The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 2The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 3The Asian arthroscopic devices market is estimated to grow to $712.3 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... Conference, SAN DIEGO, March 27 SGX Pharmaceuticals,(Nasdaq: ... the SGX523 clinical program., In January 2008, the ... SGX523 in patients with solid tumor cancers. The first,trial ... on a continuous,28-day cycle and the second trial has ...
... - GeneNews Limited (TSX: GEN),a company focused ... early,detection of diseases and personalized health management, ... fourth quarter and year ended,December 31, 2007., ... GeneNews because of the,advancements made for the ...
... Forms One of the Largest Sales Teams ... and PHILADELPHIA, March 26 /PRNewswire-FirstCall/,-- Shire plc ... company, announced today a co-promotion agreement with,TAP ... MMX(R),technology, indicated for the induction of remission ...
Cached Biology Technology:SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 2SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials 3GeneNews announces 2007 year end results 2GeneNews announces 2007 year end results 3GeneNews announces 2007 year end results 4GeneNews announces 2007 year end results 5GeneNews announces 2007 year end results 6GeneNews announces 2007 year end results 7GeneNews announces 2007 year end results 8GeneNews announces 2007 year end results 9GeneNews announces 2007 year end results 10Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 2Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 3Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 4Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis 5
...
... is a type I eukaryotic topoisomerase that ... (also called right- and left-handed supercoils) from ... reaction is a covalently closed, circular DNA ... DNA Topoisomerase I does not absolutely require ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
...
Biology Products: